THU0651 The influence of age, gender, employment status, or education on the choice of bio-similar vs. bio-original variant of the same bdmard in patients with ra or as starting biological therapy – real life data from the czech biologics registry attra

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 520
• Main Authors: Zavada, J., Nekvindova, L., Pavelka, K., Vencovsky, J.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2018
• Subjects: Age; Biological products; Employment; Etanercept; Gender; Immunotherapy; Infliximab; Maternity & paternity leaves; Monoclonal antibodies; Tumor necrosis factor-α; Czech Republic

BackgroundPerceptions on bio-originator (bo) and bio-similar (bs) biologics among HCPs and pts, as well administrative regulations or economic incentives may influence their utilisation in clinical practice. The ATTRA registry captures more than 95% of pts with RA and AS treated with biologics in th...